Target intelligence / Profile preview

Estrogen receptor alpha (Y537S mutant) (ERα (Y537S))

Target
ERα (Y537S)
Molecular classification
Receptor, Nuclear hormone receptor, Transcription factor
01

Overview

Estrogen receptor alpha (ERα), encoded by the ESR1 gene, is a ligand-activated nuclear hormone receptor and transcription factor central to the regulation of gene expression by estrogens in many tissues, including breast epithelium. **The Y537S mutation is a missense somatic mutation within the ligand-binding domain (LBD) of ERα that replaces tyrosine at position 537 with serine.** This mutation is predominantly found in hormone receptor-positive metastatic breast cancer and is linked to acquired resistance to endocrine therapies. Y537S ERα stabilizes the receptor in an agonist (active) conformation even in the absence of hormone, promoting constitutive recruitment of coactivators and continuous expression of estrogen-responsive genes. This results in **estrogen-independent tumor growth and significant resistance to antiestrogen treatments** such as tamoxifen and fulvestrant. Tumors harboring this mutation are typically more aggressive, have altered metabolic programming, and are associated with poor clinical outcome. The mutation poses a substantial therapeutic challenge and is a recognized biomarker of resistance in breast cancer treatment.

Other names
ERα Y537SESR1 Y537SEstrogen receptor 1 (Y537S mutant)Mutant ESR1 Y537S
02

Mechanism of action

Antagonism of estrogen binding (reduced efficacy in mutant) Induction of receptor degradation (partially resistant to SERDs) Inhibition of transcriptional coactivator recruitment (reduced by mutation) Antiestrogens block ER-mediated gene expression (reduced efficacy in mutant)

03

Biological functions

Transcription regulationHormone signalingCell proliferationCell survivalCell differentiation
04

Disease associations

CancerEndocrine therapy resistanceBreast cancer
05

Safety considerations

Resistance to standard endocrine therapies in breast cancer, leading to tumor progression despite therapyLimited efficacy of SERMs, SERDs, and aromatase inhibitors in mutant-expressing cancers
06

Interacting drugs

Tamoxifen

5 more in the full profile.

07

Biomarkers

Detection of Y537S ESR1 mutation in tumor DNA or ctDNA as a biomarker for endocrine therapy resistance and poor response to hormonal therapiesUpregulation of TFF1, CDK4, CD44, ERBB2, STAT3, and other proliferation markers in cells harboring the mutation

Beyond the preview

Go deeper on Estrogen receptor alpha (Y537S mutant) (ERα (Y537S)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Estrogen receptor alpha (Y537S mutant) (ERα (Y537S)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call